Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials.

Created on 13 Oct 2026

Authors

Wei-Jing Zhu, Ran An, Qian-Yun Pang, Xiao-Long Liang

Published in

Frontiers in medicine. Volume 13. Pages 1927770. Epub Sep 28, 2026.

Abstract

Chronic postsurgical pain (CPSP) poses a significant clinical burden, yet the efficacy of perioperative intravenous lidocaine for its prevention remains inconclusive. This meta-analysis evaluates its preventive efficacy and administration regimens.
PubMed, EMBASE, and the Cochrane Library were searched from database inception to a prespecified cutoff of June 1, 2025; final electronic searches were run on June 8, 2025, to identify randomized controlled trials (RCTs) comparing perioperative intravenous lidocaine with placebo/standard care in adults. Primary outcomes were CPSP incidence at 3 and 6 months postoperatively.
Eighteen RCTs (1,391 patients) were included. Intravenous lidocaine significantly reduced CPSP incidence (RR = 0.67; 95% CI: 0.53 to 0.85; P = 0.001) and neuropathic pain risk (RR = 0.60; 95% CI: 0.43 to 0.85; P = 0.004) at 3 months. However, the reduction in the incidence of CPSP was not statistically significant at 6 months (RR = 0.68; 95% CI: 0.41 to 1.12; P = 0.13). Exploratory subgroup analyses of CPSP incidence at 3 months showed favorable pooled estimates in selected surgery and administration-regimen categories; however, they did not demonstrate a statistically significant difference between regimen categories. Safety assessment was limited by inconsistent adverse-event reporting and limited pharmacokinetic monitoring.
Perioperative intravenous lidocaine reduces CPSP at 3 months, but evidence of an effect on CPSP incidence at 6 months remains inconclusive. Future trials should incorporate structured pharmacokinetic monitoring and exposure-response analyses and evaluate lidocaine's additive value alongside optimal regional anesthesia.
PROSPERO, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251063756, identifier CRD420251063756.

PMID:
42865434
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement